Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

Related Keywords

United States , Los Angeles , California , Zurcher Kantonalbank Zurich Cantonalbank , Tobin Schilke , Piper Sandler , Securities Exchange Commission , Nasdaq , Revance Therapeutics Company Profile , Goldman Sachs Group , Barclays , Los Angeles Capital Management , Revance Therapeutics Inc , Principal Financial Group Inc , Revance Therapeutics , Get Free Report , Marketbeat Ratings , Dwight Moxie , Exchange Commission , Kantonalbank Zurich Cantonalbank , Financial Group , Angeles Capital Management , Get Free , Revance Therapeutics Daily ,